| Author . | Intervention . | Effect size compared with standard of care at time . |
|---|---|---|
| McMurray et al.22 | Sacubitril/valsartan novel drug in patients with heart failure | 20% relative improvement |
| Keeley et al.23 | Primary angioplasty in acute MI | 22% relative improvement |
| RECOVERY Collaborative Group24 | Dexamethasone in severe COVID-19 pneumonia | 18–36% relative improvement depending on illness severity |
| Piazza et al.4 | CDSS alert to increase anticoagulation in high-risk hospitalized AF patients | 55% relative improvementa |
| Author . | Intervention . | Effect size compared with standard of care at time . |
|---|---|---|
| McMurray et al.22 | Sacubitril/valsartan novel drug in patients with heart failure | 20% relative improvement |
| Keeley et al.23 | Primary angioplasty in acute MI | 22% relative improvement |
| RECOVERY Collaborative Group24 | Dexamethasone in severe COVID-19 pneumonia | 18–36% relative improvement depending on illness severity |
| Piazza et al.4 | CDSS alert to increase anticoagulation in high-risk hospitalized AF patients | 55% relative improvementa |
AF, atrial fibrillation; CDSS, clinical decision support system; COVID-9, coronavirus disease 2019; MI, myocardial infarction.
Event rates and outcomes measured are omitted. These papers have been discussed at length in the literature and the focus of this comparison is to highlight the possibilities of nudges being equal in relative effect to any blockbuster, depending on the research context.
| Author . | Intervention . | Effect size compared with standard of care at time . |
|---|---|---|
| McMurray et al.22 | Sacubitril/valsartan novel drug in patients with heart failure | 20% relative improvement |
| Keeley et al.23 | Primary angioplasty in acute MI | 22% relative improvement |
| RECOVERY Collaborative Group24 | Dexamethasone in severe COVID-19 pneumonia | 18–36% relative improvement depending on illness severity |
| Piazza et al.4 | CDSS alert to increase anticoagulation in high-risk hospitalized AF patients | 55% relative improvementa |
| Author . | Intervention . | Effect size compared with standard of care at time . |
|---|---|---|
| McMurray et al.22 | Sacubitril/valsartan novel drug in patients with heart failure | 20% relative improvement |
| Keeley et al.23 | Primary angioplasty in acute MI | 22% relative improvement |
| RECOVERY Collaborative Group24 | Dexamethasone in severe COVID-19 pneumonia | 18–36% relative improvement depending on illness severity |
| Piazza et al.4 | CDSS alert to increase anticoagulation in high-risk hospitalized AF patients | 55% relative improvementa |
AF, atrial fibrillation; CDSS, clinical decision support system; COVID-9, coronavirus disease 2019; MI, myocardial infarction.
Event rates and outcomes measured are omitted. These papers have been discussed at length in the literature and the focus of this comparison is to highlight the possibilities of nudges being equal in relative effect to any blockbuster, depending on the research context.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
